Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-99712 Monotherapy or Combination with BMS-986405 in Relapsed/Refractory Multiple Myeloma
NCT04036461Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Aug 2019
- Primary completion
- Jul 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 5
01
Overview
Phase 1, open-label trial of ispectamab debotansine in multiple myeloma (MM) (2 arms), sponsored by Celgene Corporation. Primary endpoints: Adverse Events, Maximum Tolerated Dose up to 28 days and 1 more. Started Aug 2019; status: terminated.
02
Drugs
ispectamab debotansine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04036461.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04036461.